Fuchs BA, Pruett SB: Morphine induces apoptosis in murine thymocytes in vivo but not in vitro: involvement of both opiate and glucocorticoid receptors. J Pharmacol Exp Ther 1993, 266 (1) : 417–423.PubMed 34. Culler MD, Taylor JE, Moreau JP: Somatostatin receptor subtypes: targeting functional and therapeutic specificity.

Ann Endocrinol (Paris) 2002, 63 (2 Pt 3) : 2S5–12. 35. Sharma K, Patel YC, Srikant CB: Subtype-selective induction of wild-type p53 Protein Tyrosine Kinase inhibitor and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996, 10 (12) : 1688–1696.CrossRefPubMed 36. Guillermet-Guibert J, Saint-Laurent N, Davenne L, Rochaix P, Cuvillier O, Culler MD, Pradayrol L, Buscail L, Susini C, Bousquet C: Novel synergistic mechanism for sst2 somatostatin and TNFalpha receptors to induce apoptosis: crosstalk between NF-kappaB and JNK pathways. Cell Death Differ 2007, 14 (2) : 197–208.CrossRefPubMed 37. Liu HL, Huo L, Wang L: Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells. Acta Pharmacol Sin 2004, 25 (10) : 1380–1386.PubMed 38. Luciani P, Gelmini S, Ferrante E, Lania A, Benvenuti S, Baglioni S, Mantovani G, Cellai I, Ammannati F, Spada A, et al.: Expression of the antiapoptotic

gene seladin-1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2005, 90 (11) : 6156–6161.CrossRefPubMed 39. PLX4032 datasheet Kuehl WM, Bergsagel PL: Multiple myeloma: evolving genetic events

and host interactions. Nat Rev Cancer Amobarbital 2002, 2 (3) : 175–187.CrossRefPubMed 40. Moller LN, Stidsen CE, Hartmann B, Holst JJ: Somatostatin receptors. Biochim Biophys Acta 2003, 1616 (1) : 1–84.CrossRefPubMed 41. Georgii-Hemming P, Stromberg T, Janson ET, Stridsberg M, Wiklund HJ, Nilsson K: The somatostatin analog octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6-independent human multiple myeloma cell lines. Blood 1999, 93 (5) : 1724–1731.PubMed 42. Krantic S, Goddard I, Saveanu A, Giannetti N, Fombonne J, Cardoso A, Jaquet P, Enjalbert A: Novel modalities of somatostatin actions. Eur J Endocrinol 2004, 151 (6) : 643–655.CrossRefPubMed 43. Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D: Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol 2008, 14 (35) : 5377–5384.CrossRefPubMed 44. Cebon J, Findlay M, Hargreaves C, Stockler M, Thompson P, Boyer M, Roberts S, Poon A, Scott AM, Kalff V, et al.: Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer 2006, 95 (7) : 853–861.CrossRefPubMed 45. Buscail L, Esteve JP, Saint-Laurent N, Bertrand V, Reisine T, O’Carroll AM, Bell GI, Schally AV, Vaysse N, Susini C: Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms.